Everolimus News and Research

RSS

Research uncovers cells-of-origin for breast cancer in BRCA2 mutation carriers

Australian scientists have pinpointed likely 'cells-of-origin', the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease.

16 Jan 2024

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers performed a molecular analysis of neuroendocrine neoplasm (NEN) patient-derived tumor organoids (PDTOs) and their parental neoplasms.

13 Dec 2023

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

24 Oct 2023

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

22 Oct 2023

New animal model replicates the development of cardiac sarcoidosis

Sarcoidosis is an inflammatory disease in which immune cells form tissue nodules in various organs, which can drastically impair organ function.

5 Oct 2023

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Single-cell transcriptomic analysis reveals specific cellular signatures for kidney transplant rejection

Imagine a day when a urine test could inform a doctor precisely why a kidney transplant patient was experiencing organ rejection and suggest the best medication for specifically addressing the problem.

28 Jun 2023

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).

17 May 2023

Rapamycin and other rapalogs have potential to delay cancer

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, "Cancer prevention with rapamycin."

18 Apr 2023

Combinatorial biomarker predicts response to immunotherapy in kidney cancer patients

The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict — before treatment begins — how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

New mathematical model provides insight into optimal therapeutic strategies for prostate cancer

A new mathematical model which aims to optimize treatment for prostate cancer has been developed by experts at the University of Portsmouth.

1 Mar 2023

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).

28 Oct 2022

The risk of adverse reactions when herbal medications are taken with cancer drugs

A new study discusses phytovigilance initiatives based on the real-world use of herbal drugs in cancer along with conventional chemotherapy.

24 Aug 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).

13 Sep 2021

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

New method for qualifying safe drug dosing regimens in pediatrics

Determining safe yet effective drug dosages for children is an ongoing challenge for pharmaceutical companies and medical doctors alike.

6 May 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021